Gentian Diagnostics (OSE: GENT), founded in 2001, develops and manufactures high-quality, in vitro diagnostic reagents. Gentian’s expertise and focus lies within immunochemistry, specifically infections, inflammations, kidney failures and congestive heart failures. By converting existing and clinically relevant biomarkers to the most efficient automated, high-throughput analysers, the company contributes to saving costs and protecting life. Gentian is based in Moss, Norway, serving the global human and veterinary diagnostics markets through sales and representative offices in Sweden, USA and China.
The 2020 Annual General Meeting of Gentian Diagnostics AS will be held on 4th May 2020 at 10:00 (CEST) at Bjørnåsveien 5, 1596 Moss.
Please find the notice incl. appendices enclosed here:
11TH FEB - QUARTERLY REPORT- Q4
16TH APR - ANNUAL REPORT
16TH APR - QUARTERLY REPORT - Q1
4TH MAY - ANNUAL GENERAL MEETING
25TH AUG - HALF-YEARLY REPORT
21ST OCT - QUARTERLY REPORT - Q3